Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
Phase 3 clinical trial of ambroxol for Parkinson’s confirmed
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Our 2022 research summary
2022 has seen Cure Parkinson’s emerge from the COVID pandemic with a bumper year of research activity; with clinical trial results being reported and exciting, innovative research projects being awarded funding. We are proud to share this end of year summary of some of these…
STEM-ing the progression of Parkinson’s
An exciting new clinical trial called STEM-PD is due to start in Sweden and the UK which will focus on stem cell transplantation as a potential treatment for Parkinson’s.
Results of FAIRPARK-II deferiprone trial published
The results of the most recent study of deferiprone in people with Parkinson’s (the FAIRPARK-II study) have been published in the New England Journal of Medicine.
The 2022 International Linked Clinical Trials meeting
Cure Parkinson’s annually coordinates the International Linked Clinical Trials (iLCT) meeting to rank and prioritise therapies that may have the potential to modify the course of Parkinson’s progression.